Patch Biosciences
AcquiredMachine-designed sequences for safer, more effective gene therapy
- Headquarters
- Albany, New York
- Employees
- 1–10
- Founded
- 2020
- Business Model
- B2B
- Website
- patch.bio
About
Patch Biosciences was a synthetic biology and machine learning company that built an AI platform for sequence design to engineer more effective, specific, and durable genetic medicines. The company developed machine learning models and downstream assays to engineer synthetic promoters and untranslated regions (UTRs) for gene therapy, cell therapy, and RNA therapeutics applications. Backed by Andreessen Horowitz Bio+Health, Casdin Capital, and S32, Patch was acquired by Ginkgo Bioworks in February 2024, with its AI/ML capabilities integrated into Ginkgo's genetic medicine platform to accelerate programs for biopharma partners including Pfizer and Biogen.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Feb 2024
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Healthcare company in Europe
Mehiläinen is a leading Finnish private healthcare company providing medical, health, and special...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Biopharmaceutical services company